Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems
Identifieur interne : 000052 ( Istex/Corpus ); précédent : 000051; suivant : 000053Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems
Auteurs : T. Burnouf ; C. Caron ; M. Radosevich ; H. A. Goubran ; J. Goudemand ; M. El-EkiabySource :
- Haemophilia [ 1351-8216 ] ; 2008-09.
English descriptors
- Teeft :
- Assay, Authors journal compilation, Blackwell publishing, Brinogen, Burnouf, Clottable, Cryoprecipitate, Cryoprecipitate minipool, Cryoprecipitate minipools, Cryoprecipitates, Factor viii, Factor willebrand factor, Fviii, Haemophilia, Mers, Minipool, Minipools, Multimers, Normal plasma, Respective ratios, Shabrawishi hospital blood bank, Thromb, Thromb haemost, Tnbp, Triton, Viii, Viral, Viral inactivation, Willebrand, Willebrand disease, Willebrand factor.
Abstract
Summary. Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent‐detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D‐treated minipools of cryoprecipitates depleted of cryo‐poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP‐1%Triton X‐45, followed by oil extractions (n = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL−1 and 16.02 (±1.98) mg mL−1, and 8.92 (±1.05) IU mL−1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL−1, in those treated by TnBP‐Triton X‐45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL−1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD‐treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti‐A and anti‐B titre was 0–1 and 0–1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.
Url:
DOI: 10.1111/j.1365-2516.2008.01797.x
Links to Exploration step
ISTEX:FF03D89EC6C09233E9BF62E9E0446B78DE58FC50Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title><author><name sortKey="Burnouf, T" sort="Burnouf, T" uniqKey="Burnouf T" first="T." last="Burnouf">T. Burnouf</name><affiliation><mods:affiliation>Human Plasma Product Services, Research Department, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name><affiliation><mods:affiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Radosevich, M" sort="Radosevich, M" uniqKey="Radosevich M" first="M." last="Radosevich">M. Radosevich</name><affiliation><mods:affiliation>Human Plasma Product Services, Research Department, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Goubran, H A" sort="Goubran, H A" uniqKey="Goubran H" first="H. A." last="Goubran">H. A. Goubran</name><affiliation><mods:affiliation>Faculty of Medicine, Cairo University, Cairo, Egypt</mods:affiliation></affiliation></author><author><name sortKey="Goudemand, J" sort="Goudemand, J" uniqKey="Goudemand J" first="J." last="Goudemand">J. Goudemand</name><affiliation><mods:affiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="El Kiaby, M" sort="El Kiaby, M" uniqKey="El Kiaby M" first="M." last="El-Ekiaby">M. El-Ekiaby</name><affiliation><mods:affiliation>Shabrawishi Hospital Blood Bank, Cairo, Egypt</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FF03D89EC6C09233E9BF62E9E0446B78DE58FC50</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1365-2516.2008.01797.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-LWSDTNTJ-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000052</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000052</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title><author><name sortKey="Burnouf, T" sort="Burnouf, T" uniqKey="Burnouf T" first="T." last="Burnouf">T. Burnouf</name><affiliation><mods:affiliation>Human Plasma Product Services, Research Department, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Caron, C" sort="Caron, C" uniqKey="Caron C" first="C." last="Caron">C. Caron</name><affiliation><mods:affiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Radosevich, M" sort="Radosevich, M" uniqKey="Radosevich M" first="M." last="Radosevich">M. Radosevich</name><affiliation><mods:affiliation>Human Plasma Product Services, Research Department, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Goubran, H A" sort="Goubran, H A" uniqKey="Goubran H" first="H. A." last="Goubran">H. A. Goubran</name><affiliation><mods:affiliation>Faculty of Medicine, Cairo University, Cairo, Egypt</mods:affiliation></affiliation></author><author><name sortKey="Goudemand, J" sort="Goudemand, J" uniqKey="Goudemand J" first="J." last="Goudemand">J. Goudemand</name><affiliation><mods:affiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="El Kiaby, M" sort="El Kiaby, M" uniqKey="El Kiaby M" first="M." last="El-Ekiaby">M. El-Ekiaby</name><affiliation><mods:affiliation>Shabrawishi Hospital Blood Bank, Cairo, Egypt</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Haemophilia</title><title level="j" type="alt">HAEMOPHILIA</title><idno type="ISSN">1351-8216</idno><idno type="eISSN">1365-2516</idno><imprint><biblScope unit="vol">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="956">956</biblScope><biblScope unit="page" to="962">962</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-09">2008-09</date></imprint><idno type="ISSN">1351-8216</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-8216</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Assay</term><term>Authors journal compilation</term><term>Blackwell publishing</term><term>Brinogen</term><term>Burnouf</term><term>Clottable</term><term>Cryoprecipitate</term><term>Cryoprecipitate minipool</term><term>Cryoprecipitate minipools</term><term>Cryoprecipitates</term><term>Factor viii</term><term>Factor willebrand factor</term><term>Fviii</term><term>Haemophilia</term><term>Mers</term><term>Minipool</term><term>Minipools</term><term>Multimers</term><term>Normal plasma</term><term>Respective ratios</term><term>Shabrawishi hospital blood bank</term><term>Thromb</term><term>Thromb haemost</term><term>Tnbp</term><term>Triton</term><term>Viii</term><term>Viral</term><term>Viral inactivation</term><term>Willebrand</term><term>Willebrand disease</term><term>Willebrand factor</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary. Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent‐detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D‐treated minipools of cryoprecipitates depleted of cryo‐poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP‐1%Triton X‐45, followed by oil extractions (n = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL−1 and 16.02 (±1.98) mg mL−1, and 8.92 (±1.05) IU mL−1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL−1, in those treated by TnBP‐Triton X‐45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL−1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD‐treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti‐A and anti‐B titre was 0–1 and 0–1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>cryoprecipitate</json:string><json:string>brinogen</json:string><json:string>willebrand</json:string><json:string>mers</json:string><json:string>minipools</json:string><json:string>haemophilia</json:string><json:string>fviii</json:string><json:string>tnbp</json:string><json:string>multimers</json:string><json:string>triton</json:string><json:string>cryoprecipitate minipools</json:string><json:string>clottable</json:string><json:string>minipool</json:string><json:string>willebrand factor</json:string><json:string>burnouf</json:string><json:string>viral</json:string><json:string>thromb</json:string><json:string>viii</json:string><json:string>authors journal compilation</json:string><json:string>blackwell publishing</json:string><json:string>cryoprecipitates</json:string><json:string>assay</json:string><json:string>thromb haemost</json:string><json:string>willebrand disease</json:string><json:string>factor viii</json:string><json:string>viral inactivation</json:string><json:string>cryoprecipitate minipool</json:string><json:string>respective ratios</json:string><json:string>normal plasma</json:string><json:string>shabrawishi hospital blood bank</json:string><json:string>factor willebrand factor</json:string></teeft></keywords><author><json:item><name>T. BURNOUF</name><affiliations><json:string>Human Plasma Product Services, Research Department, Lille, France</json:string></affiliations></json:item><json:item><name>C. CARON</name><affiliations><json:string>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</json:string></affiliations></json:item><json:item><name>M. RADOSEVICH</name><affiliations><json:string>Human Plasma Product Services, Research Department, Lille, France</json:string></affiliations></json:item><json:item><name>H. A. GOUBRAN</name><affiliations><json:string>Faculty of Medicine, Cairo University, Cairo, Egypt</json:string></affiliations></json:item><json:item><name>J. GOUDEMAND</name><affiliations><json:string>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</json:string></affiliations></json:item><json:item><name>M. EL‐EKIABY</name><affiliations><json:string>Shabrawishi Hospital Blood Bank, Cairo, Egypt</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>cryoprecipitate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>factor VIII</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>fibrinogen</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>minipool</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>solvent‐detergent</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Von Willebrand factor</value></json:item></subject><articleId><json:string>HAE1797</json:string></articleId><arkIstex>ark:/67375/WNG-LWSDTNTJ-Q</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Summary. Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent‐detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D‐treated minipools of cryoprecipitates depleted of cryo‐poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP‐1%Triton X‐45, followed by oil extractions (n = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL−1 and 16.02 (±1.98) mg mL−1, and 8.92 (±1.05) IU mL−1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL−1, in those treated by TnBP‐Triton X‐45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL−1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD‐treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti‐A and anti‐B titre was 0–1 and 0–1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.</abstract><qualityIndicators><score>8.017</score><pdfWordCount>3257</pdfWordCount><pdfCharCount>22370</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><pdfWordsPerPage>465</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>230</abstractWordCount><abstractCharCount>1621</abstractCharCount><keywordCount>7</keywordCount></qualityIndicators><title>Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title><pmid><json:string>18565126</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Haemophilia</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1365-2516</json:string></doi><issn><json:string>1351-8216</json:string></issn><eissn><json:string>1365-2516</json:string></eissn><publisherId><json:string>HAE</json:string></publisherId><volume>14</volume><issue>5</issue><pages><first>956</first><last>962</last><total>7</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>8 and 1/32</json:string><json:string>3850</json:string><json:string>2008</json:string></date><geogName></geogName><orgName><json:string>Siemens Healthcare Diagnostics</json:string><json:string>Sigma Chemical</json:string><json:string>Cairo University</json:string><json:string>Baxter Healthcare Corp.</json:string><json:string>Shabrawishi Hospital Blood Bank, Cairo, Egypt Summary</json:string><json:string>Shabrawishi Hospital, Cairo, Egypt</json:string><json:string>Blackwell Publishing Ltd</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Sylvie Hermoire</json:string><json:string>Ahmed Abd-Allah</json:string><json:string>Dominique Jupin</json:string><json:string>Khaled Fathi</json:string><json:string>Nermin Nabil</json:string><json:string>Christine Rigalle</json:string><json:string>M. Radosevich</json:string><json:string>M. El-Ekiaby</json:string><json:string>Amr Shabrawishi</json:string></persName><placeName><json:string>Saint Jacques</json:string><json:string>Paris</json:string><json:string>Switzerland</json:string><json:string>Nancy</json:string><json:string>St Herblain</json:string><json:string>MO</json:string><json:string>USA</json:string><json:string>Cairo</json:string><json:string>Denmark</json:string><json:string>Egypt</json:string><json:string>France</json:string><json:string>St Louis</json:string><json:string>Lille</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[23]</json:string><json:string>[22]</json:string><json:string>[21]</json:string><json:string>[16]</json:string><json:string>[9,10]</json:string><json:string>[24,25]</json:string><json:string>[5]</json:string><json:string>[26]</json:string><json:string>[17,18]</json:string><json:string>[19,20]</json:string><json:string>[14]</json:string><json:string>[11,12]</json:string><json:string>[13]</json:string><json:string>[27,28]</json:string><json:string>[29,30]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-LWSDTNTJ-Q</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - hematology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - cardiovascular system & hematology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Genetics(clinical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - techniques d'exploration et de diagnostic (generalites)</json:string></inist></categories><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1111/j.1365-2516.2008.01797.x</json:string></doi><id>FF03D89EC6C09233E9BF62E9E0446B78DE58FC50</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LWSDTNTJ-Q/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LWSDTNTJ-Q/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-LWSDTNTJ-Q/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title><title level="a" type="short">CONCENTRATED S/D‐CRYOPRECIPITATES</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</licence></availability><date type="published" when="2008-09"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title><title level="a" type="short">CONCENTRATED S/D‐CRYOPRECIPITATES</title><author xml:id="author-0000"><persName><forename type="first">T.</forename><surname>BURNOUF</surname></persName><affiliation><orgName type="laboratory">Human Plasma Product Services</orgName><orgName type="laboratory">Research Department</orgName><address><addrLine>Lille</addrLine><addrLine>France</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">C.</forename><surname>CARON</surname></persName><affiliation><orgName type="laboratory">Laboratoire d’hématologie</orgName><orgName type="institution">Hôpital Régional et Universitaire</orgName><address><addrLine>Lille</addrLine><addrLine>France</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">M.</forename><surname>RADOSEVICH</surname></persName><affiliation><orgName type="laboratory">Human Plasma Product Services</orgName><orgName type="laboratory">Research Department</orgName><address><addrLine>Lille</addrLine><addrLine>France</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">H. A.</forename><surname>GOUBRAN</surname></persName><affiliation><orgName type="department">Faculty of Medicine</orgName><orgName type="institution">Cairo University</orgName><address><addrLine>Cairo</addrLine><addrLine>Egypt</addrLine><country key="EG" xml:lang="en">EGYPT</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">J.</forename><surname>GOUDEMAND</surname></persName><affiliation><orgName type="laboratory">Laboratoire d’hématologie</orgName><orgName type="institution">Hôpital Régional et Universitaire</orgName><address><addrLine>Lille</addrLine><addrLine>France</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">M.</forename><surname>EL‐EKIABY</surname></persName><affiliation><orgName type="institution">Shabrawishi Hospital Blood Bank</orgName><address><addrLine>Cairo</addrLine><addrLine>Egypt</addrLine><country key="EG" xml:lang="en">EGYPT</country></address></affiliation></author><idno type="istex">FF03D89EC6C09233E9BF62E9E0446B78DE58FC50</idno><idno type="ark">ark:/67375/WNG-LWSDTNTJ-Q</idno><idno type="DOI">10.1111/j.1365-2516.2008.01797.x</idno><idno type="unit">HAE1797</idno><idno type="toTypesetVersion">file:HAE.HAE1797.pdf</idno></analytic><monogr><title level="j" type="main">Haemophilia</title><title level="j" type="alt">HAEMOPHILIA</title><idno type="pISSN">1351-8216</idno><idno type="eISSN">1365-2516</idno><idno type="book-DOI">10.1111/(ISSN)1365-2516</idno><idno type="book-part-DOI">10.1111/hae.2008.14.issue-5</idno><idno type="product">HAE</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="956">956</biblScope><biblScope unit="page" to="962">962</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-09"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Summary. </hi> Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent‐detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D‐treated minipools of cryoprecipitates depleted of cryo‐poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP‐1%Triton X‐45, followed by oil extractions (<hi rend="italic">n</hi> = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL<hi rend="superscript">−1</hi> and 16.02 (±1.98) mg mL<hi rend="superscript">−1</hi>, and 8.92 (±1.05) IU mL<hi rend="superscript">−1</hi> in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL<hi rend="superscript">−1</hi>, in those treated by TnBP‐Triton X‐45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL<hi rend="superscript">−1</hi>, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD‐treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti‐A and anti‐B titre was 0–1 and 0–1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">cryoprecipitate</term><term xml:id="k2">factor VIII</term><term xml:id="k3">fibrinogen</term><term xml:id="k4">minipool</term><term xml:id="k5">solvent‐detergent</term><term xml:id="k6">virus</term><term xml:id="k7">Von Willebrand factor</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords><keywords rend="tocHeading2"><term>Therapy</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LWSDTNTJ-Q/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2516</doi><issn type="print">1351-8216</issn><issn type="electronic">1365-2516</issn><idGroup><id type="product" value="HAE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="HAEMOPHILIA">Haemophilia</title></titleGroup></publicationMeta><publicationMeta level="part" position="09005"><doi origin="wiley">10.1111/hae.2008.14.issue-5</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue" number="5">5</numbering></numberingGroup><coverDate startDate="2008-09">September 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="12" status="forIssue"><doi origin="wiley">10.1111/j.1365-2516.2008.01797.x</doi><idGroup><id type="unit" value="HAE1797"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title><title type="tocHeading2"><i>Therapy</i></title></titleGroup><copyright>© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</copyright><eventGroup><event type="firstOnline" date="2008-06-28"></event><event type="publishedOnlineFinalForm" date="2008-08-28"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-26"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText" date="2014-11-13"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="956">956</numbering><numbering type="pageLast" number="962">962</numbering></numberingGroup><correspondenceTo>Thierry Burnouf, PhD, HPPS, 18, rue Saint Jacques, 59800 Lille, France.
Tel.: +33 3 28 38 19 30; fax: +33 3 20 42 19 53; e‐mail: <email>tburnou@attglobal.net</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:HAE.HAE1797.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted after revision 16 May 2008</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="3"></count></countGroup><titleGroup><title type="main">Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title><title type="shortAuthors">T. BURNOUF <i>et al.</i></title><title type="short">CONCENTRATED S/D‐CRYOPRECIPITATES</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>T.</givenNames><familyName>BURNOUF</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>C.</givenNames><familyName>CARON</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>M.</givenNames><familyName>RADOSEVICH</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a3"><personName><givenNames>H. A.</givenNames><familyName>GOUBRAN</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a2"><personName><givenNames>J.</givenNames><familyName>GOUDEMAND</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a4"><personName><givenNames>M.</givenNames><familyName>EL‐EKIABY</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Human Plasma Product Services, Research Department, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="FR"><unparsedAffiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="EG"><unparsedAffiliation>Faculty of Medicine, Cairo University, Cairo, Egypt</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="EG"><unparsedAffiliation>Shabrawishi Hospital Blood Bank, Cairo, Egypt</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">cryoprecipitate</keyword><keyword xml:id="k2">factor VIII</keyword><keyword xml:id="k3">fibrinogen</keyword><keyword xml:id="k4">minipool</keyword><keyword xml:id="k5">solvent‐detergent</keyword><keyword xml:id="k6">virus</keyword><keyword xml:id="k7">Von Willebrand factor</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Summary. </b> Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent‐detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D‐treated minipools of cryoprecipitates depleted of cryo‐poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP‐1%Triton X‐45, followed by oil extractions (<i>n</i> = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL<sup>−1</sup> and 16.02 (±1.98) mg mL<sup>−1</sup>, and 8.92 (±1.05) IU mL<sup>−1</sup> in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL<sup>−1</sup>, in those treated by TnBP‐Triton X‐45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL<sup>−1</sup>, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD‐treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti‐A and anti‐B titre was 0–1 and 0–1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CONCENTRATED S/D‐CRYOPRECIPITATES</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems</title></titleInfo><name type="personal"><namePart type="given">T.</namePart><namePart type="family">BURNOUF</namePart><affiliation>Human Plasma Product Services, Research Department, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">CARON</namePart><affiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">RADOSEVICH</namePart><affiliation>Human Plasma Product Services, Research Department, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H. A.</namePart><namePart type="family">GOUBRAN</namePart><affiliation>Faculty of Medicine, Cairo University, Cairo, Egypt</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">GOUDEMAND</namePart><affiliation>Laboratoire d’hématologie, Hôpital Régional et Universitaire, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">EL‐EKIABY</namePart><affiliation>Shabrawishi Hospital Blood Bank, Cairo, Egypt</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2008-09</dateIssued><edition>Accepted after revision 16 May 2008</edition><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">3</extent></physicalDescription><abstract lang="en">Summary. Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent‐detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D‐treated minipools of cryoprecipitates depleted of cryo‐poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP‐1%Triton X‐45, followed by oil extractions (n = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL−1 and 16.02 (±1.98) mg mL−1, and 8.92 (±1.05) IU mL−1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL−1, in those treated by TnBP‐Triton X‐45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL−1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD‐treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti‐A and anti‐B titre was 0–1 and 0–1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen.</abstract><subject lang="en"><genre>keywords</genre><topic>cryoprecipitate</topic><topic>factor VIII</topic><topic>fibrinogen</topic><topic>minipool</topic><topic>solvent‐detergent</topic><topic>virus</topic><topic>Von Willebrand factor</topic></subject><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1351-8216</identifier><identifier type="eISSN">1365-2516</identifier><identifier type="DOI">10.1111/(ISSN)1365-2516</identifier><identifier type="PublisherID">HAE</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>956</start><end>962</end><total>7</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Factor replacement therapy in haemophilia – are there models for developing countries?</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Srivastava</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Srivastava A. Factor replacement therapy in haemophilia – are there models for developing countries? Haemophilia 2003; 9: 391–6.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>391</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>391</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Factor replacement for haemophilia – should cryoprecipitate be used?</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Srivastava</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Srivastava A. Factor replacement for haemophilia – should cryoprecipitate be used? Haemophilia 1999; 5: 301–5.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>301</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>301</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Choice of replacement therapy for hemophilia‐cryoprecipitate issues: a rebuttal</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Farrugia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Giangrande</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Farrugia A, Giangrande P. Choice of replacement therapy for hemophilia‐cryoprecipitate issues: a rebuttal. J Thromb Haemost 2004; 2: 1022–3.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>1022</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>J Thromb Haemost</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>1022</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Products for clotting factor replacement in developing countries</title></titleInfo><name type="personal"><namePart type="given">CK</namePart><namePart type="family">Kasper</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kasper CK. Products for clotting factor replacement in developing countries. Semin Thromb Hemost 2005; 31: 507–12.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>507</start><end>12</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Thromb Hemost</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>507</start><end>12</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Fibrinogen content of low‐volume cryoprecipitate</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Hoffman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Koepke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FK</namePart><namePart type="family">Widmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hoffman M, Koepke JA, Widmann FK. Fibrinogen content of low‐volume cryoprecipitate. Transfusion 1987; 27: 356–8.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>356</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>356</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Cryoprecipitate as a reliable source of fibrinogen replacement</title></titleInfo><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Ness</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HA</namePart><namePart type="family">Perkins</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA 1979; 241: 1690–1.</note><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>241</number></detail><extent unit="pages"><start>1690</start><end>1</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>241</number></detail><extent unit="pages"><start>1690</start><end>1</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion‐transmitted infection</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Pereira</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion‐transmitted infection. Haematologica 2007; 92: 846–9.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>846</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Haematologica</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>846</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Commercial fibrinogen, autogenous plasma, whole blood and cryoprecipitate for coagulum pyelolithotomy: a comparative study</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Marshall</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marshall S. Commercial fibrinogen, autogenous plasma, whole blood and cryoprecipitate for coagulum pyelolithotomy: a comparative study. J Urol 1978; 119: 310–401.</note><part><date>1978</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><extent unit="pages"><start>310</start><end>401</end></extent></part><relatedItem type="host"><titleInfo><title>J Urol</title></titleInfo><part><date>1978</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><extent unit="pages"><start>310</start><end>401</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Blood supply and demand</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Blood supply and demand. Lancet 2005; 365: 2151.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>365</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Hemophilia treatment. Predicting the long‐term risk of HIV exposure by cryoprecipitate</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Evatt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Austin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Leon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Ruiz‐Saez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">De Bosch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Evatt B, Austin H, Leon G, Ruiz‐Saez A, De Bosch N. Hemophilia treatment. Predicting the long‐term risk of HIV exposure by cryoprecipitate. Haemophilia 2000; 6: 128–32.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>128</start><end>32</end></extent></part><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>128</start><end>32</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>A minipool process for solvent‐detergent treatment of cryoprecipitate at blood centres using a disposable bag system</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Burnouf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HA</namePart><namePart type="family">Goubran</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Radosevich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Sayed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Gorgy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">El‐Ekiaby</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El‐Ekiaby M. A minipool process for solvent‐detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 2006; 91: 56–62.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>56</start><end>62</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>56</start><end>62</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Preparation and viral inactivation of cryoprecipitate in blood banks in resource‐limited countries</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Burnouf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Goubran</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Radosevich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">El‐Ekiaby</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnouf T, Goubran H, Radosevich M, El‐Ekiaby M. Preparation and viral inactivation of cryoprecipitate in blood banks in resource‐limited countries. ISBT Sci Ser 2007; 2: 121–8.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>121</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>ISBT Sci Ser</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>121</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Clauss</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237–40.</note><part><date>1957</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>237</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>Acta Haematol</title></titleInfo><part><date>1957</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>237</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Content and functional activity of von Willebrand factor in apheresis plasma</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Burnouf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Caron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Burkhardt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Goudemand</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnouf T, Caron C, Burkhardt T, Goudemand J. Content and functional activity of von Willebrand factor in apheresis plasma. Vox Sang 2004; 87: 27–33.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>27</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>27</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>A multicenter evaluation of STA‐LIATEST VWF: a new latex particle immunoassay for von Willebrand factor antigen</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Eby</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Chance</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Oliver</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eby C, Chance D, Oliver D. A multicenter evaluation of STA‐LIATEST VWF: a new latex particle immunoassay for von Willebrand factor antigen. Clin Hemost Rev 1997; 11: 16–7.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>16</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Hemost Rev</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>16</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand’s disease</title></titleInfo><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Favaloro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Grispo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Exner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Koutts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand’s disease. Blood Coagul Fibrinolysis 1991; 2: 285–91.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>285</start><end>91</end></extent></part><relatedItem type="host"><titleInfo><title>Blood Coagul Fibrinolysis</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>285</start><end>91</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>The complex multimeric composition of factor VIII/von Willebrand factor</title></titleInfo><name type="personal"><namePart type="given">ZM</namePart><namePart type="family">Ruggeri</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TS</namePart><namePart type="family">Zimmerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140–3.</note><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>1140</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>1140</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mazurier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Samor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goudemand</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61–4.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>61</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>61</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Aronson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997; 78: 930–3.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>930</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>930</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Comparative study on collagen‐binding enzyme‐linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor</title></titleInfo><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Turecek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Siekmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Schwarz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Turecek PL, Siekmann J, Schwarz HP. Comparative study on collagen‐binding enzyme‐linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Semin Thromb Hemost 2002; 28: 149–60.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>149</start><end>60</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Thromb Hemost</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>149</start><end>60</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Menache</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Aronson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Menache D, Aronson DL. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78: 566–70.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>566</start><end>70</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>566</start><end>70</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>A comparative multi‐laboratory assessment of three factor VIII/von Willebrand factor concentrates</title></titleInfo><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Favaloro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Bukuya</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Martinelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Favaloro EJ, Bukuya M, Martinelli T et al. A comparative multi‐laboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 2002; 87: 466–76.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>466</start><end>76</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>466</start><end>76</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand’s disease</title></titleInfo><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Favaloro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Koutts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand’s disease. Pathology 1997; 29: 385–91.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>385</start><end>91</end></extent></part><relatedItem type="host"><titleInfo><title>Pathology</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>385</start><end>91</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Plasma exchange with solvent/detergent‐treated plasma of resistant thrombotic thrombocytopenic purpura</title></titleInfo><name type="personal"><namePart type="given">CN</namePart><namePart type="family">Harrison</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Lawrie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Iqbal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Hunter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Machin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ. Plasma exchange with solvent/detergent‐treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94: 756–8.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>756</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>756</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method</title></titleInfo><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Keeling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Luddington</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Allain</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Lawrie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Williamson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Keeling DM, Luddington R, Allain JP, Lawrie AS, Williamson LM. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 1997; 96: 194–7.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>194</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>194</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>In vitro study of a triple‐secured von Willebrand factor concentrate</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mazurier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Poulle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Samor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Hilbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Chtourou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S. In vitro study of a triple‐secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100–4.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>100</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>100</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease</title></titleInfo><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Mannucci</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mannucci PM. Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease. Haemostasis 1994; 24: 285–8.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>285</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Haemostasis</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>285</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Characterization of von Willebrand factor in factor VIII concentrates</title></titleInfo><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Fricke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MY</namePart><namePart type="family">Yu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fricke WA, Yu MY. Characterization of von Willebrand factor in factor VIII concentrates. Am J Hematol 1989; 31: 41–5.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>41</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Hematol</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>41</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease</title></titleInfo><name type="personal"><namePart type="given">AB</namePart><namePart type="family">Federici</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Mannucci</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Federici AB, Mannucci PM. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998; 4: 7–10.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>7</start><end>10</end></extent></part><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>7</start><end>10</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America</title></titleInfo><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Cohen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Kessler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BM</namePart><namePart type="family">Ewenstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 235–41.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>235</start><end>41</end></extent></part><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>235</start><end>41</end></extent></part></relatedItem></relatedItem><identifier type="istex">FF03D89EC6C09233E9BF62E9E0446B78DE58FC50</identifier><identifier type="ark">ark:/67375/WNG-LWSDTNTJ-Q</identifier><identifier type="DOI">10.1111/j.1365-2516.2008.01797.x</identifier><identifier type="ArticleID">HAE1797</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LWSDTNTJ-Q/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000052 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000052 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FF03D89EC6C09233E9BF62E9E0446B78DE58FC50
|texte= Properties of a concentrated minipool solvent‐detergent treated cryoprecipitate processed in single‐use bag systems
}}
| This area was generated with Dilib version V0.6.33. |  |